- Home
- MGTX vs LAB Comparison
MGTX vs LAB Comparison
Compare MGTX & LAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGTX
- LAB
- Stock Information
- Founded
- MGTX 2015
- LAB 1999
- Country
- MGTX United States
- LAB United States
- Employees
- MGTX N/A
- LAB N/A
- Industry
- MGTX Biotechnology: Biological Products (No Diagnostic Substances)
- LAB Biotechnology: Laboratory Analytical Instruments
- Sector
- MGTX Health Care
- LAB Industrials
- Exchange
- MGTX Nasdaq
- LAB Nasdaq
- Market Cap
- MGTX 479.9M
- LAB 562.1M
- IPO Year
- MGTX N/A
- LAB 2011
- Fundamental
- Price
- MGTX $7.30
- LAB $1.30
- Analyst Decision
- MGTX Strong Buy
- LAB Strong Buy
- Analyst Count
- MGTX 2
- LAB 2
- Target Price
- MGTX $23.50
- LAB $2.88
- AVG Volume (30 Days)
- MGTX 278.8K
- LAB 1.8M
- Earning Date
- MGTX 03-13-2025
- LAB 02-26-2025
- Dividend Yield
- MGTX N/A
- LAB N/A
- EPS Growth
- MGTX N/A
- LAB N/A
- EPS
- MGTX N/A
- LAB N/A
- Revenue
- MGTX $13,929,000.00
- LAB $155,902,000.00
- Revenue This Year
- MGTX N/A
- LAB $62.60
- Revenue Next Year
- MGTX $1,391.84
- LAB $9.19
- P/E Ratio
- MGTX N/A
- LAB N/A
- Revenue Growth
- MGTX 108.24
- LAB 48.23
- 52 Week Low
- MGTX $3.85
- LAB $1.17
- 52 Week High
- MGTX $7.80
- LAB $3.04
- Technical
- Relative Strength Index (RSI)
- MGTX 66.58
- LAB 35.51
- Support Level
- MGTX $6.72
- LAB $1.17
- Resistance Level
- MGTX $7.06
- LAB $1.51
- Average True Range (ATR)
- MGTX 0.37
- LAB 0.10
- MACD
- MGTX 0.05
- LAB 0.00
- Stochastic Oscillator
- MGTX 71.61
- LAB 32.50
About MGTX MeiraGTx Holdings plc
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.
About LAB Standard BioTools Inc.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.